Alvotech S.A (ALVO) | Stock Overview & Key Data
Alvotech S.A Performance Comparison
Stock Range
Today's Range
Low: $8.33
High: $8.52
on August 22, 2025
52 Week Range
Low: $7.35
High: $13.70
on April 9, 2025
on January 13, 2025
All-Time High: $18.00 on February 26, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.7B
EPS
0.23
P/E Ratio (TTM)
38.04
Forward P/E
43.75
P/B Ratio
N/A
PEG Ratio
43.75
Div. Yield
N/A
ROE
56.17%
Beta
0.111
Debt to Equity
-7.32
Financial Highlights
Profitability
Gross Margin
57.39%
Operating Margin
10.42%
Profit Margin
11.26%
Returns and Earnings
Return on Assets (TTM)
2.83%
Return on Equity (TTM)
56.17%
EBITDA
$101.9M
Net Income (TTM)
$63.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.86
Quarterly Revenue Growth (YoY)
-12.80%
Quarterly Earnings Growth (YoY)
-50.90%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Alvotech S.A ALVO | 2.73B Mid-cap | -0.12% | -1.97% | -16.63% | -31.03% | -35.64% | -28.68% | -3.64% | -12.58% |
| Zoetis ZTS | 65.30B Large-cap | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% | -16.11% | -9.09% | -2.69% |
| Haleon Plc - ADR HLN | 43.42B Large-cap | 1.13% | 2.94% | -11.62% | -2.68% | 3.92% | -0.91% | 57.46% | 32.39% |
| Elanco Animal Health ELAN | 8.70B Mid-cap | -2.83% | 19.14% | 38.59% | 58.71% | 45.15% | 20.04% | 13.72% | -39.96% |
| Regencell Bioscience RGC | 6.08B Mid-cap | -1.10% | -12.78% | 15.02% | 10,366.67% | 9,561.54% | 5,609.09% | 1,531.17% | 4,385.71% |
| Alkermes plc ALKS | 4.80B Mid-cap | 2.83% | 9.00% | -4.81% | -17.72% | 1.08% | 3.97% | 18.42% | 77.74% |
Ownership & Short Interest
Insider Ownership
61.79%
Institutional Ownership
6.49%
Shares Short
1M
Short Ratio
3.44
Short % of Shares Outstanding
0.92%
Average 10-Day Volume
565K
Average 90-Day Volume
420K
Alvotech S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Alvotech S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ALVO's 52-week high and low?
- In the last 52 weeks, Alvotech S.A reached a high of $13.70 (on January 13, 2025) and a low of $7.35 (on April 9, 2025).
- What is the market cap and P/E ratio for ALVO?
- Curious about Alvotech S.A's size and valuation? Its market capitalization stands at 2.73B. When it comes to valuation, the P/E ratio (trailing twelve months) is 38.04, and the forward P/E (looking ahead) is 43.75.
- Does ALVO pay dividends? If so, what's the yield?
- As for dividends, Alvotech S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Alvotech S.A's main competitors or similar companies to consider before investing?
When looking at Alvotech S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.30B Healthcare Drug Manufacturers - Specialty & Generic -16.11% -9.09% Haleon Plc - ADR
HLN43.42B Healthcare Drug Manufacturers - Specialty & Generic -0.91% 57.46% Elanco Animal Health
ELAN8.70B Healthcare Drug Manufacturers - Specialty & Generic 20.04% 13.72% Regencell Bioscience
RGC6.08B Healthcare Drug Manufacturers - Specialty & Generic 5,609.09% 1,531.17% Alkermes plc
ALKS4.80B Healthcare Drug Manufacturers - Specialty & Generic 3.97% 18.42% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Alvotech S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Alvotech S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 56.17%, the Debt to Equity ratio from the most recent quarter is -7.32, and its Gross Profit Margin stands at 57.39%.
- What is the recent revenue and earnings growth for ALVO?
- Looking at Alvotech S.A's growth, its revenue over the trailing twelve months (TTM) was $562M. Compared to the same quarter last year (YoY), quarterly revenue grew by -12.80%, and quarterly earnings saw a YoY growth of -50.90%.
- How much of ALVO stock is held by insiders and institutions?
- Wondering who owns Alvotech S.A stock? Company insiders (like executives and directors) hold about 61.79% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 6.49%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.